Biophan-die neue Microsoft?!
Seite 110 von 113 Neuester Beitrag: 26.07.23 00:01 | ||||
| Eröffnet am: | 15.05.04 09:58 | von: aida73 | Anzahl Beiträge: | 3.824 |
| Neuester Beitrag: | 26.07.23 00:01 | von: MrTrillion3 | Leser gesamt: | 388.459 |
| Forum: | Hot-Stocks | Leser heute: | 300 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 108 | 109 | | 111 | 112 | ... 113 > | ||||
hier nochmal das Quiz in meinem beitrag vom 23.01.2008
"ein bisschen Spass muss sein ... trala trala" ????
vielleicht so in Abwandlung von einem Schlager - ein bisschen Spass muss sein, dann kommt biophan von ganz allein
wobei bei biophan scheinst du nicht mehr auf dem Laufenden zu sein / oder du bist nicht Aktionär oder hast den Brief von Lanzafame vom 16.01.2008 noch nicht zugestellt bekommen; denn wenn doch, wäre dir mit Sicherheit mehr auf- und eingefallen
http://www.biophan.com/...ion=com_content&task=view&id=475&Itemid=212
hier mal etwas, was mich als Nicht-Mediziner daraus interessieren würde
Zitat aus dem Brief: "... In addition, the company is working on developing some of its other early stage technologies, such as pulsewidth modulation for tissue stimulation, which can be used to excite nerve tissues in a manner that is far more energy efficient than any existing stimulation device. This technology may have the capability to take the efficiency of pacemakers, ICDs, and neurostimulators to a new level, and we are seeking grant funding to support further development..."
mich würde doch schon interessieren, was dir als biophan -Veteran bei ariva hierzu einfallen könnte (Historie, Fakten, mögliche Zusammenhänge...??)
zu den anderen dort angesprochenen Themen kannst du dich natürlich auch äußern, wobei mir aus Erfahrung klar sein sollte, dass du es lieber magst, auf den Positionen anderer rumzuhacken, als etwas eigenes substanzielles zur Diskussion zu stellen
Deshalb kannst du auch weitermachen wie bisher, denn ein bisschen Spass kann sein, dann kommt biophan von ganz allein!!!
Schöner Brief, was solls, man kann es für voll nehmen oder auch nicht, bisher war an den Aussagen der Firma nicht viel wahres dran.
Man hat einen abgehalfterten Neuen aufgenommen. Ist das jetzt was gutes oder schlechtes? Ich sehe nichts gutes daran, sowas gibt es überall und immer wieder. Beispiel Herr Ahn von Hana. Bei Genentech einen guten, gutbezahlten Job aufgegeben (müssen?) Bei Hana abkassiert, die Karre in den Mist gefahren und von der Bildfläche verschwunden.
pulsewidth modulation sagt mir nichts. Wird da ein neues Märchen angefangen? Was soll eigentlich noch die Herzschrittmachertechnologie nachdem die Patente dafür verkauft sind? Vielleicht könnte das eine Verbesserung werden mit der man zwar nichts anfangen kann, aber vielleicht könnte man die dann ebenfalls an Medtronic verkaufen was wieder etwas Geld bringen würde. Da das aber erst angefangen wird kann man darüber mal in 7-10 JAhren reden.
Von den 11 Mio die man für die Herzschrittmacher-Patente bekommen hat dürfte nur noch die Hälfte übrig sein.
Daß man nur noch von 45 Patente redet wundert dich nicht? Es waren mal fast 4 mal so viel.
Kein Wort mehr zu Stent, Filter, Drug delivery, Motor und was sie früher mal alles hatten, oder gerne gehabt hätten. Die Batterie ist auf Eis gelegt und es wurde ja mal in einer früheren News geschrieben, (genaue Asusdrucksweise weiß ich nicht mehr) dass es eventuell nicht zu erreichen ist die Batterie auf die erforderliche Größe zu bekommen. Was das mit den 200000 $ ist habe ich nicht mitbekommen, ich kann mich an keine Meldung erinnern in der das angesprochen wurde. Stand diese Einnahmen im letzten Bericht?
Das einzige was also noch von dieser, früher mal (angeblich ) gut gefüllten Pipeline übrig geblieben ist, das ist der Myovad. Jetzt kann man sich überlegen ob man nach dieser Historie der Firma glaubt das es diesmal anders ist, oder verschwindet es am Ende wie so vieles ebenfalls ganz unspektakulär im Biotech Nirvana?
Du hast übrigens immer noch nicht gesagt was du an der Firmengeschichte so gut findest, und nicht vergessen, Geschichte ist nicht nur das letzte JAhr.
Apr 08, 2008 07:00 ET
Biophan Announces Memorandum of Understanding Between Myotech and PPA Technologies
PITTSFORD, NY--(Marketwire - April 8, 2008) - Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced that Myotech, the company's majority-owned subsidiary, has entered into a Memorandum of Understanding with PPA Technologies to explore the potential for a strategic relationship regarding the development and commercialization of their respective technologies.
PPA Technologies AG Jena, a German company, is developing a technical solution for active support in cases of cardiac insufficiency and complete temporary support during cardiac arrest. This technology could be complementary to the Myotech Circulatory Support System (CSS), which is intended to improve the treatment of acute heart failure.
John Lanzafame, Biophan's CEO, said, "We have entered into this agreement to explore the potential for collaboration between the two companies, to strengthen our product offerings and infrastructure. Both companies are approaching a similar segment of the heart failure market, and the possible synergies between the companies and our respective technologies hold the potential to put us in a much stronger competitive position. Myotech has approached this market need from a surgical viewpoint, while PPA has approached the market need from the perspective of the interventional cardiologist, so there may be a combination that could provide us a broader offering of products. Initial meetings and discussions have been positive, and with this memorandum of understanding, we can explore and formalize the best alternative for a closer working relationship."
The Myotech Circulatory Support System (CSS) consists of an external drive unit and flexible polymer cup that slips over the heart and is designed to provide the energy that enables the heart to restore normal blood flow. It is designed to be deployed quickly for use in resuscitation and insufficient cardiac output indications. Since it will have no contact with circulating blood, the Myotech CSS is expected to reduce the risk of patient complications, such as clotting and stroke, bleeding, and infection.
About Biophan Technologies, Inc.
Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which is intended to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 68% interest in Myotech. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expect, or believe may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Carolyn Hotchkiss
Biophan Technologies, Inc.
Communications Manager
(585) 267-4800
Email Contact
aus dem S-1 vom 25.10.2007
COMPETITION
......
In the area of cardiovascular support, there are several manufacturers of circulatory support systems, including Abiomed, Thoratec, World Heart, and others. In the area of acute heart failure, where restoration of cardiac output is needed for an arrested heart, there are no circulatory systems known to the Company that can provide full systolic and diastolic support to an arrested heart, without blood contact, as quickly as the Myotech circulatory support system. PPA Technologies AG, in Germany, is developing a device that provides non-blood contacting support, their patents a r e n o t widely filed outside of Germany and d o n o t cover many of the features and full range of capabilities of the Myotech CSS.
nur so als Ansatz (für mich) - wenn am anfängt sich und anderen Fragen stellen möchte
PPA ist jetzt nicht aus dem Nichts gekommen, über die hatten wir schon vor langer Zeit schon mal geredet. Weiß nicht mehr wie lange das her ist, - über 2 Jahre? Aber da du ja von der Geschichte Biophans so begeistert bist weißt du auch was vor 2-6 Jahren so alles los war.
Und wenn du das, was ich bisher zu ppa gelesen habe, wenn überhaupt, etwas wesentliches gewesen sein soll, dann bringt es auch nichts, wenn wir beide uns in eine Diskussion einlassen. Von der Analyse her denke ich für mich, bringt es etwas, wenn man das was du als Müll bezeichnest mit den Gedanken aus dem S-1 in Zusammenhang bringt.
Biophan Expands Intellectual Property Portfolio With Two New Patents
Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced the expansion of its intellectual property portfolio for development in new technical markets, with the availability of two US patents.
Biothermal Power Source for Implantable Devices
This patent, US 7,340,304, is the third issued patent licensed to Biophan from Biomed Solutions LLC, and covers the generation of electrical power from body heat for implantable devices. This patent deals with specialized device shape and construction that enables the biothermal power source to take advantage of higher temperatures found deeper in the body, thus providing higher output of electrical power. Biophan has continued its work with personnel at the NASA Ames Research Center to improve the conversion efficiency of the semiconductor materials used to convert thermal to electrical energy. This patent represents an additional system-level approach to getting further power improvements.
Optical MRI Catheter System
US/2005-0197563, a patent application assigned directly to Biophan, has been allowed by the USPTO, and will soon issue as a US patent. This application discloses details of the construction and operation of a specialized catheter having a highly miniaturized MRI coil that can be guided into coronary arteries. "Vulnerable plaque" is the term used to describe those regions in the arterial wall most likely to shed a blood clot, widely regarded to cause 75% of heart attacks and a large percentage of strokes. Biophan intends to use one or more optical fibers in place of electrical conductors within the catheter. These fibers have extremely high signal carrying capacity, and would help eliminate risks due to catheter heating during an MRI procedure.
"These patents provide the potential to broaden the reach and the scope of our technology beyond its current focus," said John Lanzafame, Chief Executive Officer of Biophan. "We will continue to pursue grant funding opportunities for development of these and other technologies for which the company has patent protection, while moving forward with the continued development of the Myotech Cardiac Support System (CSS)."
About Biophan Technologies, Inc.
Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 68% interest in Myotech with rights to acquire additional equity, and is leading Myotech's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expect, or believe may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact:
Carolyn Hotchkiss
Biophan Technologies, Inc.
Communications Manager
(585) 267-4800
Email Contact
CES
Mir ist nicht bekannt, daß im Zusammenhang mit den Lizenzabkommen irgendwann die Rede davon war, daß Biophan aus den Einnahmen daraus an irgendjemand was abgeben muß. Das wurde wohl so nebenbei unter den Teppich gekehrt. Naja, passt ja zur ganzen Firmenpolitik, Anlegerverarschung eben.
SOURCE: Biophan Technologies, Inc.
May 13, 2008 07:00
ETBiophan Acquires Intellectual Property Portfolio of Nanoset, LLC
PITTSFORD, NY--(Marketwire - May 13, 2008) - Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced that the Company has acquired the patent portfolio of Nanoset, LLC, a private company and technology collaborator.
The Nanoset intellectual property acquisition includes over 15 issued patents and a number of patent applications covering various uses of nanomagnetic materials, including MRI image compatibility and novel materials and methods for targeted drug delivery. This technology was previously licensed to Biophan, but was limited to medical fields. This acquisition removes the limitation, providing additional license opportunities for this unique technology which also has applications in the communications and defense industries.
John Lanzafame, Biophan's CEO, stated, "This acquisition provides a number of benefits to Biophan. The applications for MRI image compatibility are included in our license to Boston Scientific, and this purchase eliminates an outgoing royalty obligation for the Company. In addition, we will target grants and strategic partnerships to develop some of the other applications for this technology, including therapeutic delivery and non-medical applications, opening up additional licensing opportunities."
Biophan acquires patent portfolio of Nanoset
14th May 2008
By Staff Writer
Biophan Technologies, a developer of next-generation biomedical technology, has acquired the patent portfolio of Nanoset, a private company and technology collaborator.
The Nanoset intellectual property acquisition includes over 15 issued patents and a number of patent applications covering various uses of nanomagnetic materials, including magnetic resonance imaging (MRI) image compatibility and novel materials and methods for targeted drug delivery. This technology was previously licensed to Biophan, but was limited to medical fields. This acquisition removes the limitation, providing additional license opportunities for this unique technology which also has applications in the communications and defense industries.
John Lanzafame, Biophan's CEO, said: "This acquisition provides a number of benefits to Biophan. The applications for MRI image compatibility are included in our license to Boston Scientific, and this purchase eliminates an outgoing royalty obligation for the company. In addition, we will target grants and strategic partnerships to develop some of the other applications for this technology, including therapeutic delivery and non-medical applications, opening up additional licensing opportunities."
Bid 0,027€
Ask 0,029€
CES